תחזית צמיחת רווחים לשנה הבאה: Passage Bio Corp (PASG)

Passage Bio, Inc. (PASG) is developing neurogenic therapy in collaboration with the University of Pennsylvania, accelerating global trials. The estimated growth in net earnings per share for the coming year reflects market expectations, with the indicator valued at -4.20. The company relies on future sales of pediatric brain medications, although the business is exposed to binary risks due to its narrow specialization in viral vectors.

This indicator serves as a filter for stress-testing positions by identifying the gap between current value and future returns. The metric measures the percentage change in the consensus earnings per share (EPS) forecast, updating data daily to eliminate market distortions. Analyzing the 12-month expected EPS growth chart is critical for Passage Bio, Inc. (PASG), as a potential monopoly in CNS gene therapy allows for the integration of ultra-high pricing into forecasts.